Blood markers to predict severe and long-term effects of leptospirosis
Identification of predictive biomarkers for severe acute leptospirosis and its long-term sequelae
Looking for blood markers that predict which people with leptospirosis will become seriously ill or develop long-term problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Chulalongkorn University NIH-funded |
| Lab location | 1 site (Bangkok, THAILAND) |
| Project ID | NIH-11166694 on NIH RePORTER |
What this research studies
If you join, researchers will examine blood samples and medical records from people with confirmed leptospirosis, using samples already stored in a biorepository and new samples collected over time. They will run protein, cytokine, and gene-expression tests on the blood and use machine learning to find patterns that separate patients who had severe disease from those who did not. The team will link early blood changes to later outcomes like kidney or lung failure and long-term complications by following patients over months to years. This work is carried out by experts collaborating at Chulalongkorn University and partner centers experienced in leptospirosis care.
Who could benefit from this research
Good fit: Ideal candidates are people with confirmed acute leptospirosis, especially early in their illness, who can give blood samples and agree to follow-up visits.
Not a fit: People without leptospirosis, those with unrelated illnesses, or those unable to provide early blood samples or follow-up data are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, doctors could identify high-risk patients earlier and provide closer monitoring or targeted treatments to prevent organ failure and long-term disability.
How similar studies have performed: Some prior studies have found individual inflammation and kidney-injury markers in leptospirosis, but using multi-omics combined with machine learning to predict severe and long-term outcomes is relatively new.
Where this research is happening
Bangkok, THAILAND
- Chulalongkorn University — Bangkok, Thailand (Active)
Researchers
- Principal investigator: Srisawat, Nattachai — Chulalongkorn University
- Study coordinator: Srisawat, Nattachai
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.